Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867905 · ClinicalTrials.gov registry record
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
A clinical trial of Septic Shock and Bacteremia, sponsored by University of British Columbia.
- Completed
- Registry status
- 330
- Enrollment target
- 7
- Study locations
NCT01867905: Completed study of Septic Shock and Bacteremia, sponsored by University of British Columbia.
NCT01867905 is a study of Septic Shock and Bacteremia that has completed, run by University of British Columbia. The registered enrollment target is 330 participants, below the 5,045-participant average among 24 other Septic Shock trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01867905, a study of Septic Shock and Bacteremia, has completed, sponsored by University of British Columbia.
- COMPLETED
- Registry status
- 330 participants
- Enrollment target
- 7
- Study locations
Study Summary
Sepsis is a significant cause health care expenditure and carries an extremely high rate of morbidity and mortality if not treated appropriately. From 1979 to 2000, sepsis resulted in over 10 million admissions to hospital in the United States with a mortality rate of 17.9 to 27.8 percent. In Canada, it is estimated that the incidence of sepsis from 2008-2009 was 103.3 per 100,000 per year. Advances in the multifaceted management of sepsis in recent years have resulted in improved clinical outcomes. However, the cornerstone of sepsis management relies on the prompt administration of appropriate antibiotics. Current clinical practice suggests that antibiotic administration can be delayed up to 45 minutes in order to obtain blood cultures, whose results have a profound impact on the type and duration of antimicrobial therapy. Unfortunately, this recommendation is based on very little evidence and the investigators have found that potential life-saving treatment is often delayed in order to abide by it. Furthermore, recent data suggest that mortality could be increased by approximately 5% by delaying antibiotic administration for that time period. The investigators therefore wish to organize a prospective, multi-centre trial in order to identify the effect of antibiotic administration on blood culture positivity in patients presenting with severe sepsis or septic shock. Other objectives will be to elucidate which patient factors, including age, co-morbid conditions and clinical presentation, as well as antibiotic choice will affect blood culture results. This study will be conducted in the emergency departments at St. Paul's Hospital (SPH), Vancouver General Hospital (VGH), Lion's Gate Hospital (LGH), Surrey Memorial Hospital, Montreal General Hospital (MGH), Royal Victoria Hospital (RVH) and Maricopa Integrated Health System. Patients identified for the aforementioned conditions will be treated as per routine hospital protocol. If the patient is deemed eligible for
Primary Outcome
The primary outcome is the measure of blood culture positivity before and after antibiotic administration.
Conditions Studied
Study Locations (7)
British Columbia
- Lions Gate Hospital - North Vancouver
- Surrey Memorial Hospital - Surrey
- Vancouver General Hospital - Vancouver
- Saint-Paul's Hospital - Vancouver
Quebec
- Montreal General Hospital - Montreal
- Royal Victoria Hospital - Montreal
Arizona
- Maricopa Integrated Health Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2019-04-10 |
What the finished NCT01867905 record still lists
NCT01867905 is an observational study that tracks outcomes without assigning an intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 5,045-participant average among 24 other Septic Shock trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Septic Shock appearing as the primary indexed condition, and to 0 interventions.
NCT01867905 lists 7 locations in 3 states (British Columbia, Quebec, Arizona).
Frequently Asked Questions
What is clinical trial NCT01867905 about?
NCT01867905 is a clinical study titled "Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock". Sepsis is a significant cause health care expenditure and carries an extremely high rate of morbidity and mortality if not treated appropriately. From 1979 to 2000, sepsis resulted in over 10 million admissions to hospital in the United States with a mortality rate of 17.9 to 27.8 percent. In Canada...
What is the current status of trial NCT01867905?
This trial is currently completed. The enrollment target is 330 participants. The study started on 2014-03-01. Estimated completion is 2019-04-10.
What conditions does trial NCT01867905 study?
This clinical trial studies the following conditions: Septic Shock, Bacteremia, Severe Sepsis.
Who is sponsoring clinical trial NCT01867905?
This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01867905 being conducted?
This trial has 7 study locations across Arizona, British Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01867905's enrollment target sits among peer trials
330 10th of 24 higher than 15 of 24 other Septic Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Septic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
-
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RECRUITING · Phase 3
-
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
RECRUITING · NA
-
Assessment for Implementation Methods in Sepsis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI